Skip to main content
. Author manuscript; available in PMC: 2022 Apr 9.
Published in final edited form as: ACS Infect Dis. 2021 Mar 10;7(4):894–905. doi: 10.1021/acsinfecdis.0c00917

Table 2A.

Antibacterial activity of rifampicin, PMB alone and PMB in the presence of 1μg/ml Rifampicin versus polymyxin-susceptible and polymyxin-resistant strains

compound AlogP E.coli ATTC 25922 K.pneumoniae ATCC 13882 P.aeruginosa ATCC 27853 A.baumannii NCTC 13301 E.coli IHMA940398 E.coli CDF1 K.pneumoniae IHMA580884 K.pneumoniae IHMA520329 P.aeruginosa IHMA644636 P.aeruginosa IHMA517175 A.baumannii IHMA517303 A.baumanni IHMA 851735
Rifampicin N/A 4 16 16 4 8 8 16 32 16 16 2 4
PMB (1) −6.3 0.25 0.125 0.25 0.125 16 4 8 64 64 8 >64 4
PMB (1) plus 1μg/ml Rifampicin −6.3 ≤0.015 0.06 0.125 ≤0.015 0.06 0.06 0.06 0.125 0.5 0.25 0.125 ≤0.015